Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic science and translational research

3003 - Lurbinectedin (PM01183) exhibits antitumor activity in PARP-inhibitor resistant germline BRCA PDX and lacks cross-resistance with cisplatin


08 Oct 2016


Basic science and translational research


Cristina Cruz


Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392


C. Cruz1, G. Caratu2, A. Llop-Guevara3, M. Castroviejo3, S. Gutierrez-Enriquez4, B. Morancho5, E. Álvarez de la Campa6, L. Prudkin7, P. Nuciforo7, J. Arribas5, A. Vivancos2, X. de la Cruz6, C. Galmarini8, P.M. Avilés9, C. Saura1, O. Díez4, V. Serra3, J. Balmaña10

Author affiliations

  • 1 Medical Oncology, Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 2 Cancer Genomics Group, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 3 Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 4 Oncogenetics Group, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 5 Growth Factors Laboratory, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 6 Translational Bioinformatics And Computational Biology, Vall d'Hebron Institute of Research, Barcelona/ES
  • 7 Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 8 Cell Biology And Pharmacogenomics, PharmaMar S.A., Madrid/ES
  • 9 Non Clinical Toxicology And Pharmacology, PharmaMar S.A., Madrid/ES
  • 10 Medical Oncology, Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology, Barcelona/ES


Abstract 3003


PM01183, a trabectedin analogue that inhibits transactivated transcription and induces DNA double-strand breaks, displays remarkable clinical activity in germline BRCA (gBRCA)-related metastatic breast cancer (MBC). However, the mechanisms of primary and acquired resistance to PM01183 and their potential impact on the efficacy of other active agents, namely PARP inhibitors (PARPi) and platinum salts, are unknown. This knowledge may help to delineate the optimal therapeutic sequence to maximize the clinical benefit in the metastatic setting.


We assessed the antitumor activity of PM01183 (0.18mg/kg IV) and cisplatin (6mg/kg IV) q7dx5 in a panel of 10 gBRCA PDXs from PM01183-naïve patients (8 PARPi-resistant and 2 PARPi-sensitive), and one additional PDX implanted at PM01183 progression. Additionally, we performed exome sequencing analysis in baseline (pre-treatment, n = 5) and paired tumor biopsies (pre- and post-treatment, n = 5) from patients treated with PM01183.


PM01183 exhibited antitumor activity (partial response, complete response or stabilization) in 75% (6/8) of the PARPi-resistant PDXs. These results suggest that the mechanisms of resistance to PARPi do not confer resistance to PM01183. Exome sequencing of gBRCA PM01183-resistant tumors unveiled the presence or acquisition of genetic alterations that may disrupt the nucleotide excision repair (NER) pathway in 5 samples, which may impair sensitivity to PM01183. Conversely, these alterations confer sensitivity to cisplatin in vitro and in the clinic. Accordingly, the PDX model implanted at progression to PM01183 showed PM01183 resistance but cisplatin sensitivity. These results suggest that NER alterations potentially driving resistance to PM01183 do not compromise cisplatin efficacy.


Our results on cross-resistance in gBRCA MBC suggest that PM01183 is active in the context of PARPi resistance, and that PM01183 resistance will not interfere on platinum efficacy.

Clinical trial identification

Legal entity responsible for the study



Pharmamar S.A.


C. Galmarini, P.M. Avilés: Empoyee at PharmaMar S.A. J. Balmaña: Non-commercial research agreement with PharmaMar S.A. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings